1068874--10/12/2006--IMPLANT_SCIENCES

related topics

{product, liability, claim}

{product, market, service}

{product, candidate, development}

{interest, director, officer}

{property, intellectual, protect}

{personnel, key, retain}

{stock, price, share}

{debt, indebtedness, cash}

{customer, product, revenue}

{control, financial, internal}

The Company has received a modified audit opinion on its ability to continue as a going concern. We do not operate at a profit and do not expect to be profitable for some time. Intense competition and rapid technological change could harm our financial performance. Our medical products and technologies may not be accepted by the medical community which could harm our financial performance. Our explosives detection products and technologies may not be accepted by government agencies, airports or airlines which could harm our future financial performance. Our future profitability depends on whether our products can successfully compete in the There are risks relating to our Development, Distribution and Manufacturing Agreement with Rapiscan Systems, Inc. Limitations on our ability to protect our intellectual property or continue to use our intellectual property could harm our financial performance. Our medical device products and services are subject to extensive government regulation. If we fail to obtain or are delayed in obtaining the approval of the necessary federal and state government agencies, our business could be materially affected. We depend on third party reimbursement to our customers for market acceptance of our medical products. If third party payors fail to provide appropriate levels of reimbursement for our products, our profitability would be adversely affected. Product liability claims could damage our reputation and hurt our financial results. If our contract manufacturer cannot provide the services we require, our ability to manufacture our products could be harmed. If we were to lose the services of either our president or our chief scientist, our business would be adversely affected. We will be required to redeem the Series D Preferred for cash if the five day average market price of our common stock, prior to a redemption date, is less than 110% of the fixed conversion price. If third party credit is unavailable, our working capital could be restricted; restrictions on our ability to raise additional capital under certain circumstances.

Full 10-K form ▸

1068874--10/12/2006--IMPLANT_SCIENCES_CORP